Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

BMS 354825

Known as: 354825, BMS, BMS-354825, BMS354825 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2006
Highly Cited
2006
Dasatinib (BMS-354825), a novel dual SRC/BCR-ABL kinase inhibitor, exhibits greater potency than imatinib mesylate (IM) and… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2006
Highly Cited
2006
Activating mutations of the activation loop of KIT are associated with certain human neoplasms, including the majority of… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2006
Highly Cited
2006
Chronic myeloid leukemia (CML) is caused by the constitutively activated tyrosine kinase breakpoint cluster (BCR)-ABL. Current… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2006
Highly Cited
2006
BMS-354825 (dasatinib) and AMN107 (nilotinib) are potent alternate Abl inhibitors with activity against many imatinib mesylate… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2
Is this relevant?
Highly Cited
2006
Highly Cited
2006
Mastocytosis is associated with an activating mutation in the KIT oncoprotein (KITD816V) that results in autophosphorylation of… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2006
Highly Cited
2006
Mutations of the epidermal growth factor receptor (EGFR) selectively activate Akt and signal transducer and activator of… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Imatinib, a Bcr-Abl tyrosine kinase inhibitor, is a highly effective therapy for patients with chronic myelogenous leukemia (CML… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Src family kinases (SFK) are currently being investigated as targets for treatment strategies in various cancers. The novel SFK… Expand
  • figure 1
  • figure 3
  • figure 2
  • figure 4
Is this relevant?
Highly Cited
2004
Highly Cited
2004
A series of substituted 2-(aminopyridyl)- and 2-(aminopyrimidinyl)thiazole-5-carboxamides was identified as potent Src/Abl kinase… Expand
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Resistance to the ABL kinase inhibitor imatinib (STI571 or Gleevec) in chronic myeloid leukemia (CML) occurs through selection… Expand
Is this relevant?